What is endometriosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The most effective approach to managing endometriosis involves a combination of medical therapies and surgical excision by a specialist, with preoperative imaging playing a crucial role in reducing morbidity and mortality. Endometriosis is a common condition impacting approximately 10% of individuals assigned female at birth 1. The disorder is caused by endometrial-like tissue located outside of the endometrial cavity, associated with inflammation and fibrosis, on or extending below the peritoneal surface 1.

Diagnosis and Treatment

The diagnosis of endometriosis is challenging due to variable presenting symptoms and nonspecific physical examination findings 1. Historically, the diagnosis of endometriosis was made by diagnostic laparoscopy with histologic inspection. However, studies have shown that preoperative imaging is associated with decreased morbidity and mortality and reduces the need for repeat surgeries by reducing the number of incomplete surgeries 1.

Some key points to consider in the management of endometriosis include:

  • The use of expanded protocol transvaginal ultrasound (TVUS) studies to identify and “map” deep endometriosis (DE) 1
  • The importance of special training for performing these expanded TVUS examinations, which are associated with a learning curve of at least 40 examinations 1
  • The recommendation to use an MRI protocol tailored for detection of DE, with moderate bladder distention and vaginal contrast to help improve lesion conspicuity involving these structures 1
  • The potential role of fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET/CT and the radiopharmaceutical fluoroestradiol in detecting endometriosis, although further research is needed 1

Quality of Life and Morbidity

The clinical presentation of endometriosis is variable, ranging from asymptomatic to severe symptoms that interfere with daily activity 1. Pelvic pain is the most common symptom, which can manifest as dysmenorrhea, dyspareunia, dyschezia, dysuria, or menorrhagia. Approximately one-half of patients with endometriosis experience infertility 1. Treatment of endometriosis should prioritize reducing morbidity and mortality, while also improving quality of life, and may involve a combination of medical therapies and surgical excision by a specialist. Health care spending on endometriosis is similar to other chronic diseases with an estimated annual economic burden of $69.4 billion 1.

In terms of specific treatments, options may include:

  • Medical therapies such as nonsteroidal anti-inflammatory drugs (NSAIDs) or hormonal treatments like combined oral contraceptives or GnRH agonists
  • Surgical options ranging from conservative laparoscopy to remove endometriotic lesions while preserving fertility, to hysterectomy with removal of ovaries in severe cases when fertility is no longer desired
  • The use of preoperative imaging to inform patient decision making, surgical planning, and management 1

From the Research

Definition and Prevalence of Endometriosis

  • Endometriosis is a chronic benign disease that affects women of reproductive age, with a prevalence of about 10% 2.
  • It is characterized by the presence of endometrial-like tissue outside the uterus, leading to various symptoms such as pain and infertility.

Medical Treatment Options

  • Medical therapy is often the first line of management for women with endometriosis, aiming to ameliorate symptoms or prevent post-surgical disease recurrence 3.
  • Available medical options include:
    • Non-steroidal anti-inflammatory drugs (NSAIDs) for relieving primary dysmenorrhea 3.
    • Combined oral contraceptives and progestins as first-line hormonal therapies, which have been shown to improve pain symptoms in the majority of patients 3, 2.
    • Gonadotropin-releasing hormone-agonists (GnRH agonists) for women who do not respond to first-line therapies, although they have a less favorable tolerability profile 3.
    • Gonadotropin-releasing hormone antagonists, which have shown promise in late-stage clinical development 3, 4.

Hormonal Treatments

  • Hormonal treatments aim to block menstruation or cause pseudodecidualization, impairing the progression of endometriotic implants 5.
  • Options include:
    • GnRH agonists and antagonists, which act on pituitary-ovarian function 5.
    • Progestins, such as dienogest, which act on multiple sites of action 5.
    • Combined oral contraceptives, which inhibit ovarian function 5.
  • Add-back therapy, including estrogens, may be used to prevent bone loss and improve quality of life 6.

Current Research and Future Directions

  • Research is ongoing to develop new treatments for endometriosis, including selective progesterone receptor modulators, selective estrogen receptor modulators, and aromatase inhibitors 5.
  • Oral GnRH antagonists, such as elagolix, relugolix, and linzagolix, have shown efficacy in reducing endometriosis-associated pain and are currently being investigated in clinical trials 4.

Related Questions

What is endometriosis?
What are the treatment options for endometriosis?
What are the treatment options for endometriosis?
What are the treatment options for endometriosis?
What are the treatment options for endometriosis?
What is the mechanism of Calcitonin Gene-Related Peptide (CGRP) receptors?
What is the likely diagnosis with an absolute CD3+ and CD8+ count of 113 cells and an elevated Immunoglobulin G (IgG) level of 1730?
Is fecal incontinence due to myelopathy (spinal cord injury or disease) ever reversible?
What is the differential diagnosis for a 22-year-old female who presents with a syncopal (syncope) episode following an epistaxis (nose bleed)?
How do you minimize aspiration risk in a patient with Intracranial Hemorrhage (ICH)?
What is the diagnosis for a patient with cardiomegaly, pulmonary vascular congestion, bilateral interstitial opacities, likely representing pulmonary edema, leukocytosis (White Blood Cell count of 14.2), anemia (Red Blood Cell count of 4.15), macrocytosis (Mean Corpuscular Volume of 102.2), elevated Red Cell Distribution Width (RDW of 55.3), neutrophilia (Segmented Neutrophil Absolute count of 12.2), lymphopenia (Lymphocyte Absolute count of 0.7), elevated C-Reactive Protein (CRP of 85.5), normal Procalcitonin (0.32), elevated D-Dimer (1.65), hyperglycemia (Glucose of 156), elevated Blood Urea Nitrogen (BUN of 30), impaired renal function (Creatinine of 2.04, Glomerular Filtration Rate of 33), hyponatremia (Sodium of 135), and cellulitis of the left hand?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.